Physician profile
Eric Shoemaker
NPI 1851749147
$2,025.89
in general payments reported to CMS, 2019-2025
28 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $177 · 2021: $237 · 2022: $466 · 2023: $273 · 2024: $275 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.22 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Novo Nordisk INC | $269.56 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $172.24 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $142.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $138.98 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $130.33 | 2020-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $95.26 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.40 | 2019-2025 | Jardiance |
| Viiv Healthcare Company | $52.84 | 2024 | Apretude |
| Abbott Laboratories | $45.12 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $42.90 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $41.21 | 2022-2024 | Qelbree |
| Lundbeck LLC | $40.12 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $38.81 | 2019-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $38.30 | 2024-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.07 | 2022-2023 | Vaxneuvance, Proquad, Gardasil 9 |
| Gilead Sciences, INC. | $29.65 | 2021-2025 | |
| Alkermes, INC. | $28.42 | 2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $27.18 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.29 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $18.22 | 2025 | Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.50 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $16.27 | 2025 | Eliquis |
| Amgen INC. | $15.71 | 2022 | |
| Corium, LLC | $14.12 | 2024 | Azstarys |
| Astellas Pharma US INC | $13.86 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $13.24 | 2020 | |
| Medline Industries Lp | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.